Shuttle Pharmaceuticals Holdings, Inc.
SHPH Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$5.05
KIRA · Stoqly’s AI analyst, in plain words
- Shuttle Pharmaceuticals Holdings, Inc. lost $11.7M in fiscal 2025.
Market cap
$5.1M
P/E
0.2x
Revenue
—
Net income
−$11.7M
Free cash flow
—
Operating margin
—
Shuttle Pharmaceuticals Holdings, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$11.7M
No. It lost money last year.
How is the share priced?
0.2x
One share costs 0.2 times its yearly profit per share.
What Shuttle Pharmaceuticals Holdings, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- Shuttle Pharmaceuticals Holdings, Inc.
- CIK
- 0001757499
Shuttle Pharmaceuticals Holdings, Inc. · SHPH
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | $0.1M | $0.1M | — |
| Revenue growth | — | — | — | 0.0% | — |
| Net interest income | — | — | $0.1M | $0.1M | — |
| Operating margin | — | — | −5,892.4% | −7,696.2% | — |
| Net income | −$1.2M | −$5.0M | −$6.6M | −$9.1M | −$11.7M |
| Net margin | — | — | −6,592.7% | −9,144.8% | — |
| Diluted EPS | — | −$5.04 | −$3.53 | −$82.60 | −$7.16 |
| Cash | |||||
| Cash from operations | −$0.3M | −$2.7M | −$5.6M | −$7.3M | −$9.5M |
| Capital expenditure | — | — | $0.0M | — | — |
| Free cash flow | — | — | −$5.6M | — | — |
| FCF margin | — | — | −5,600.1% | — | — |
| Share count change | — | — | 39.5% | −93.8% | 1,318.1% |
| Debt and strength | |||||
| Cash and short-term investments | $0.5M | $8.4M | $5.5M | $1.9M | $0.3M |
| Debt incl. finance leases | $0.1M | — | — | — | — |
| Deposits | — | — | $0.0M | — | — |
| Shareholders' equity | −$1.8M | $7.7M | $4.1M | $0.7M | $2.3M |
| Current ratio | 0.2x | 8.8x | 5.4x | 1.4x | 0.1x |
| Interest coverage | −458.7x | −2.6x | −2.8x | — | — |
| Returns and quality | |||||
| Return on equity | — | −169.0% | −112.4% | −383.8% | −791.0% |
| Return on tangible equity | — | −87.9% | −162.5% | −1,289.5% | — |
| Piotroski F-score | — | — | — | 3 | — |
| Altman Z'' | −105.2 | 5.1 | −13.3 | −63.4 | −26.4 |
Insiders bought, 12 months
$0.2M
1 insider
Insiders sold, 12 months
$0.5M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Shuttle Pharmaceuticals Holdings, Inc. · SHPH
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $5.05 a share, the company is worth $5.1M: 0.2 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001757499). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.